The COVID-19 vaccine continues to save lives, proving the vaccination strategy paid off and was a worthwhile national ...

Pfizer faces growth challenges with patent losses and waning COVID sales. Selling an ATM Put option expiring Nov'25 could ...

A passion for learning took her from apartheid South Africa to a beer brewery to becoming a healthcare consultant, all before ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Officials say the Army has reenlisted more than 23 soldiers who were discharged for refusing the COVID-19 vaccine.

PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). If Pfizer and Moderna can ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

The Kansas Supreme Court is weighing whether to block a sweeping state law that lets workers easily bypass COVID-19 vaccine ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...